<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:47:46Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:7180420" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:7180420</identifier>
        <datestamp>2020-04-29</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="pmc">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC7180420</article-id>
              <article-id pub-id-type="pmcid">PMC7180420</article-id>
              <article-id pub-id-type="pmc-uid">7180420</article-id>
              <article-id pub-id-type="pmid">32324238</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2020.3482</article-id>
              <article-id pub-id-type="publisher-id">zoi200164</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Critical Care Medicine</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Azithromycin Treatment vs Placebo in Children With Respiratory Syncytial Virus–Induced Respiratory Failure</article-title>
                <subtitle>A Phase 2 Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Azithromycin (AZM) Treatment in Children With Respiratory Syncytial Virus (RSV)–Induced Respiratory Failure</alt-title>
                <alt-title alt-title-type="running-head">Azithromycin (AZM) Treatment in Children With Respiratory Syncytial Virus (RSV)–Induced Respiratory Failure</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Kong</surname>
                    <given-names>Michele</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Zhang</surname>
                    <given-names>Wei Wei</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Sewell</surname>
                    <given-names>Kate</given-names>
                  </name>
                  <degrees>RN</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Gorman</surname>
                    <given-names>Gregory</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff2">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kuo</surname>
                    <given-names>Hui-Chien</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Aban</surname>
                    <given-names>Inmaculada</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Ambalavanan</surname>
                    <given-names>Namasivayam</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Whitley</surname>
                    <given-names>Richard J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref ref-type="aff" rid="zoi200164aff1">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi200164aff1"><label>1</label>Department of Pediatrics, University of Alabama at Birmingham</aff>
              <aff id="zoi200164aff2"><label>2</label>McWhorter School of Pharmacy, Samford University, Birmingham, Alabama</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> February 21, 2020.</p>
                <p content-type="published-online"><bold>Published:</bold> April 23, 2020. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2020.3482</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/pages/instructions-for-authors#SecOpenAccess">CC-BY License</ext-link>. © 2020 Kong M et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi200164cor1"><bold>Corresponding Author:</bold> Michele Kong, MD, Department of Pediatrics, University of Alabama at Birmingham, 1600 Fifth Ave S, PPS 102, Birmingham, AL 35233 (<email xlink:href="mkong@peds.uab.edu">mkong@peds.uab.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Kong had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Ambalavanan and Whitley contributed equally to this work.</p>
                <p><italic>Concept and design:</italic> Kong, Aban, Ambalavanan, Whitley.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> All authors.</p>
                <p><italic>Drafting of the manuscript:</italic> Kong, Sewell, Gorman, Aban, Ambalavanan.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Kong, Zhang, Gorman, Kuo, Aban, Ambalavanan, Whitley.</p>
                <p><italic>Statistical analysis:</italic> Kong, Kuo, Aban.</p>
                <p><italic>Obtained funding:</italic> Kong.</p>
                <p><italic>Administrative, technical, or material support:</italic> Kong, Zhang, Sewell, Gorman, Ambalavanan, Whitley.</p>
                <p><italic>Supervision:</italic> Whitley.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Aban reported receiving grants from the National Institutes of Health, the Myasthenia Gravis Foundation of America, Alexion, argenx, Catalyst Pharmaceutical, RA Pharmaceutical, and the Transverse Myelitis Association outside the submitted work. Dr Amabalavanan reported receiving grants from the National Institutes of Health during the conduct of the study. Dr Whitley reported receiving grants from the National Institutes of Health during the conduct of the study and receiving personal fees from Gilead Sciences outside the submitted work. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was funded by grant UL1TR003096 from the <funding-source rid="sp1">University of Alabama at Birmingham Center for Clinical and Translational Science</funding-source>.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> We thank the members of the data and safety monitoring board, Nancy Tofil, MD (chair; University of Alabama at Birmingham), Kim Benner, PharmD (McWhorter School of Pharmacy), Stephen Robert, MD (Cedars Sinai), Charity Morgan, PhD (University of Alabama at Birmingham), and David Kimberlin, MD (University of Alabama at Birmingham), for their time and oversight. We thank the Department of Pediatrics Research Office and the University of Alabama at Birmingham Center for Clinical and Translational Science for their ongoing support of this work. Finally, we thank the members of the scientific oversight committee, David Redden, PhD (University of Alabama at Birmingham), and Steven Rowe, MD (University of Alabama at Birmingham), for their insights. None of these individuals were compensated for their time.</p>
                <p><bold>Additional Information:</bold> Because of a data entry oversight in ClinicalTrials.gov, the primary outcomes were originally listed only as azithromycin pharmacokinetics, oxygen support, and multiorgan system failure scores. No secondary outcomes were listed. We provided regulatory documentation, including institutional review board and Investigational New Drug submissions and approvals that confirmed studies performed prospectively on these children, with the primary and secondary outcomes as stated in the manuscript.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2020-04-23T10:00">
                <day>23</day>
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>23</day>
                <month>4</month>
                <year>2020</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and
						0 days and was based on the <pub-date
						pub-type="epub"/>. -->
              <volume>3</volume>
              <issue>4</issue>
              <elocation-id>e203482</elocation-id>
              <history>
                <date date-type="received">
                  <day>13</day>
                  <month>12</month>
                  <year>2019</year>
                </date>
                <date date-type="accepted">
                  <day>21</day>
                  <month>2</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2020 Kong M et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-3-e203482.pdf">jamanetwopen-3-e203482.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2020.3482"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi200164-1">
                  <title>Question</title>
                  <p>Is azithromycin (AZM) safe, and does it reduce nasal and endotracheal matrix metalloproteinase 9 (MMP-9) levels in children with respiratory syncytial virus–induced respiratory failure?</p>
                </sec>
                <sec id="ab-zoi200164-2">
                  <title>Findings</title>
                  <p>In this randomized phase 2 clinical trial that included 48 children admitted to the pediatric intensive care unit with respiratory syncytial virus lung disease who required positive pressure ventilation, AZM was safe. No difference in nasal MMP-9 levels was observed between treatment group, but in those who required mechanical ventilation and received a high dose of AZM, endotracheal active and total MMP-9 levels were lower on day 3 of treatment.</p>
                </sec>
                <sec id="ab-zoi200164-3">
                  <title>Meaning</title>
                  <p>In this study, high doses of AZM were safe, reduced endotracheal MMP-9 levels in patients receiving mechanical ventilation, and potentially improved outcomes in critically ill children with respiratory syncytial virus infections.</p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser">
                <p>This phase 2 randomized clinical trial investigates the safety of azithromycin for children with respiratory syncytial virus–induced respiratory failure and assesses the effect of azithromycin therapy on nasal matrix metalloproteinase 9 levels.</p>
              </abstract>
              <abstract>
                <sec id="ab-zoi200164-4">
                  <title>Importance</title>
                  <p>Despite a high disease burden, there is no effective treatment for respiratory syncytial virus (RSV) infection.</p>
                </sec>
                <sec id="ab-zoi200164-5">
                  <title>Objectives</title>
                  <p>To determine whether administration of azithromycin (AZM) to children with RSV-induced respiratory failure is safe and to define the effect of AZM therapy on nasal matrix metalloproteinase 9 (MMP-9) levels.</p>
                </sec>
                <sec id="ab-zoi200164-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This randomized, double-blind, placebo-controlled phase 2 trial was conducted at a single tertiary pediatric intensive care unit from February 2016 to February 2019. The study included children with RSV infection who were admitted to the pediatric intensive care unit and required respiratory support via positive pressure ventilation (invasive and noninvasive). A total of 147 children were screened; 90 were excluded for not meeting inclusion criteria, having an absent legal guardian, lacking pharmacy support, or having a language barrier and 9 declined participation, resulting in 48 patients enrolled in the study.</p>
                </sec>
                <sec id="ab-zoi200164-7">
                  <title>Intervention</title>
                  <p>Receipt of standard dose AZM (10 mg/kg/d), high-dose AZM (20 mg/kg/d), or a matching placebo of normal saline intravenously for 3 days.</p>
                </sec>
                <sec id="ab-zoi200164-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Nasal and endotracheal samples were collected at baseline as well as at 24 hours and 48 hours after start of treatment. The secondary outcome was to determine treatment effect on clinical outcome measures, including days of positive pressure ventilation and length of hospital stay.</p>
                </sec>
                <sec id="ab-zoi200164-9">
                  <title>Results</title>
                  <p>A total of 48 patients were enrolled in the trial, with a median (range) age at randomization of 12 (1 to 125) months; 36 participants (75.0%) were younger than 2 years. Overall, 26 participants (54.2%) were boys, and 29 (60.4%) had a comorbidity. A total of 16 patients were randomized into each trial group (ie, placebo, standard-dose AZM, and high-dose AZM). Baseline demographic characteristics were comparable among the 3 groups. Both doses of AZM were safe, with no adverse events observed. No difference in nasal MMP-9 levels were observed between treatment groups. Among those who required mechanical ventilation and received high-dose AZM, endotracheal active and total MMP-9 levels were lower on day 3. Compared with baseline, active and total MMP-9 levels in endotracheal aspirates were 1.0 log lower in the high-dose AZM group (active MMP-9: 99.8% CI, −1.28 to −0.64; <italic>P</italic> &lt; .001; total MMP-9: 99.8% CI, −1.37 to −0.57; <italic>P</italic> &lt; .001). Patients who received high-dose AZM had fewer median (interquartile range) hospital days compared with those receiving the placebo (8 [6-14] days vs 11 [8-20] days; mean ratio estimate, 0.57; 95% CI, 0.38-0.87; <italic>P</italic> = .01).</p>
                </sec>
                <sec id="ab-zoi200164-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this phase 2 randomized clinical trial, both doses of AZM were safe. While nasal MMP-9 levels were unchanged among treatment groups, endotracheal MMP-9 levels were lower among those who received high-dose AZM. The positive secondary clinical outcome, while exploratory, provides insight for end points in a multicenter randomized trial.</p>
                </sec>
                <sec id="ab-zoi200164-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT02707523?cond=NCT02707523&amp;draw=2&amp;rank=1">NCT02707523</ext-link></p>
                </sec>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source id="sp1">University of Alabama at Birmingham Center for Clinical and Translational Science</funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI200164">
              <title>Introduction</title>
              <p>Respiratory syncytial virus (RSV) infection has a substantial global disease burden.<sup><xref rid="zoi200164r1" ref-type="bibr">1</xref>,<xref rid="zoi200164r2" ref-type="bibr">2</xref>,<xref rid="zoi200164r3" ref-type="bibr">3</xref>,<xref rid="zoi200164r4" ref-type="bibr">4</xref></sup> Matrix metalloproteinases (MMPs) are proteases implicated in the pathogenesis of both acute and chronic lung disease.<sup><xref rid="zoi200164r5" ref-type="bibr">5</xref>,<xref rid="zoi200164r6" ref-type="bibr">6</xref>,<xref rid="zoi200164r7" ref-type="bibr">7</xref>,<xref rid="zoi200164r8" ref-type="bibr">8</xref>,<xref rid="zoi200164r9" ref-type="bibr">9</xref>,<xref rid="zoi200164r10" ref-type="bibr">10</xref>,<xref rid="zoi200164r11" ref-type="bibr">11</xref></sup> In 2015, we reported<sup><xref rid="zoi200164r12" ref-type="bibr">12</xref></sup> that early elevation of endotracheal MMP-9 levels was positively associated with RSV disease severity and that MMP-9 inhibition decreased RSV replication in a murine model, suggesting that MMP-9 might be a potential marker of disease severity and a therapeutic target in RSV disease.</p>
              <p>Macrolides are a class of antibiotics that are known to penetrate cells, making them active against intracellular pathogens; azithromycin (AZM) is reported to have a long intracellular half-life.<sup><xref rid="zoi200164r13" ref-type="bibr">13</xref></sup> In addition, AZM is an immune modulator that has been reported to provide clinical benefit in inflammatory airway diseases.<sup><xref rid="zoi200164r14" ref-type="bibr">14</xref>,<xref rid="zoi200164r15" ref-type="bibr">15</xref></sup> Therefore, we performed a randomized, placebo-controlled phase 2 trial to test the hypothesis that AZM therapy during RSV-induced respiratory failure was safe and would reduce nasal and lung MMP-9 levels as well as to explore preliminary effects on the disease course for planning a subsequent definitive trial.</p>
            </sec>
            <sec id="H1-2-ZOI200164">
              <title>Methods</title>
              <sec id="H2-1-ZOI200164">
                <title>Participants</title>
                <p>Eligible participants included all children admitted to the pediatric intensive care unit (PICU) at Children’s of Alabama (Birmingham) with a diagnosis of RSV infection and requiring positive pressure ventilation, invasive or noninvasive, including bilevel positive airway pressure (BiPAP) or high-flow nasal cannula (HFNC) oxygen (ie, &gt;1 L/kg/min of flow, with ≥5 L/min flow for children weighing &lt;5 kg). When the trial began in February 2016, it only included patients with RSV with respiratory failure requiring mechanical ventilation, but in December 2016, it was expanded to include patients with respiratory failure supported on noninvasive positive pressure ventilation. This was to reflect the overall change in the PICU’s practice whereby more patients had a trial of management using BiPAP or HFNC before mechanical ventilation. Exclusion criteria included use of AZM within 7 days of PICU admission, any contraindication to AZM use, cardiac arrhythmias, electrocardiogram with QT interval corrected for heart rate of at least 450 milliseconds, history of pyloric stenosis, and receipt of immunosuppressant.</p>
                <p>During hospitalization, all patients were treated according to the American Academy of Pediatrics guidelines for the management of bronchiolitis,<sup><xref rid="zoi200164r16" ref-type="bibr">16</xref></sup> primarily supportive care. The study protocol was approved by the University of Alabama at Birmingham institutional review board, and a data and safety monitoring board serially evaluated the study. An Investigational New Drug approval was obtained from the US Food and Drug Administration for the use of AZM in this trial (Investigational New Drug number, 127632). Participants’ legal guardians provided written informed consent before randomization into the trial. The Consolidated Standards of Reporting Trials (<ext-link ext-link-type="uri" xlink:href="https://www.equator-network.org/reporting-guidelines/consort/">CONSORT</ext-link>) guideline was used for the reporting of this trial.<sup><xref rid="zoi200164r17" ref-type="bibr">17</xref></sup> The trial protocol is available in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 1</xref>.</p>
              </sec>
              <sec id="H2-2-ZOI200164">
                <title>Study Design and Treatment</title>
                <p>The study was a double-masked, placebo-controlled parallel group trial with 3 treatment groups. All participants, their families, health care professionals, and study staff were masked to study medication allocation, with the exception of the biostatistician and the pharmacist. Participants were randomized according to a permuted-block design to receive either placebo (saline) or AZM (Fresenius Kabi) at 10 mg/kg/d (ie, standard dose) or 20 mg/kg/d (ie, high dose) intravenously every 24 hours for 3 days. The randomization schedule was created by the study biostatistician and provided to the study pharmacist for implementation.</p>
                <p>Nasal and endotracheal samples (if intubated) were collected from all participants before treatment as well as at 24 hours and at 48 hours after treatment started. For patients who were intubated, only nasal samples were collected once extubated. No long-term follow-up was performed.</p>
                <p>The study spanned 3.5 RSV seasons, from February 2016 to February 2019. Owing to the initial age restriction placed by the Food and Drug Administration, the first 9 participants enrolled were older than 6 months. Once this number was reached and no safety concerns were evident as determined by the data and safety monitoring board, infants younger than 6 months were eligible for enrollment in the study.</p>
                <p>The primary outcomes of this trial were as follows: (1) to ascertain the safety of AZM and its pharmacokinetics and (2) to determine whether treatment with AZM resulted in decreased nasal MMP-9 levels. When the study protocol was expanded to include patients who were not ventilated, the primary outcome also changed from endotracheal MMP-9 levels to nasal MMP-9 levels. The secondary outcomes were to determine the in vivo efficacy of AZM administration on improving clinical outcome measures, specifically duration of ventilatory support and oxygenation as well as PICU and hospital lengths of stay.</p>
              </sec>
              <sec id="H2-3-ZOI200164">
                <title>Nasal and Endotracheal Aspirate Collection and Processing</title>
                <p>Nasal samples were collected using a nasal swab inserted through the nares. The swab was then immediately placed in a vial containing 3 mL of viral transport media (Quidel). Endotracheal aspirates were collected via endotracheal tube suctioning using an 8 French suction cannula (CareFusion) and centrifuged at 500<italic>g</italic> for 10 minutes to separate supernatant from cells and mucus (pellet). All samples were kept at 4 °C for further analysis.</p>
              </sec>
              <sec id="H2-4-ZOI200164">
                <title>Assay of AZM and Urea Levels and Pharmacokinetic Analysis</title>
                <p>We measured AZM and urea levels in endotracheal and plasma samples using liquid chromatography–tandem mass spectrometric assays. Dilution estimations of endotracheal samples were calculated using the urea dilution method.<sup><xref rid="zoi200164r18" ref-type="bibr">18</xref></sup> Peak plasma levels (C<sub>max</sub>) and time to C<sub>max</sub> (T<sub>max</sub>) of AZM were determined by visual evaluation of the concentration vs time profile. The area under the curve (AUC) values were calculated using the trapezoidal rule. The half-life (t<sub>1/2</sub>) of AZM was calculated as natural log of 2 / k<sub>e</sub>, in which <italic>k<sub>e</sub></italic> was the terminal elimination rate constant estimated by linear regression analysis of the terminal portion of the concentration-time profile. Penetration ratios for AZM in samples from the endotracheal compartment were calculated as the AUC of the endotracheal compartment divided by the AUC of plasma.</p>
              </sec>
              <sec id="H2-5-ZOI200164">
                <title>Biologic Outcome Measurement</title>
                <p>Measurement of active MMP-9, total MMP-9, and tissue inhibitor of metalloproteinase 1 (TIMP-1) were done using established fluorometric assays (F9M00 and DTM100, respectively; R&amp;D Systems). Interleukin 1 (IL-1), IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, tumor necrosis factor α (TNF-α), and interferon γ (IFN-γ) were analyzed via electrochemiluminescence using the Meso Scale Discovery V-PLEX Cytokine Panel 1 Human Kit (K15049D-1; Meso Scale Diagnostics). We measured RSV loads by reverse-transcription quantitative polymerase chain reaction using known concentrations of RSV to derive a standard curve.<sup><xref rid="zoi200164r19" ref-type="bibr">19</xref></sup> Standards and negative controls were included and tested with each polymerase chain reaction assay. We reported RSV quantification as log<sub>10</sub> copies per mL.</p>
              </sec>
              <sec id="H2-6-ZOI200164">
                <title>Clinical Data Assessment</title>
                <p>The clinical data collected included duration of respiratory support (focusing on days of mechanical ventilation, noninvasive positive pressure ventilation via BiPAP or HFNC, and total duration of supplemental oxygen), PICU stay, and hospital stay. Comorbidities and the presence of multiorgan failure<sup><xref rid="zoi200164r20" ref-type="bibr">20</xref></sup> were also identified.</p>
              </sec>
              <sec id="H2-7-ZOI200164">
                <title>Sample Size Determination and Statistical Analysis</title>
                <p>This study was designed to have a total sample of 48 participants divided in 3 groups, with 16 per group, to detect a 25% and 37.5% decrease in lung MMP-9 activity in the standard-dose and high-dose groups, respectively, relative to placebo, with 80% power using analysis of variance. The assumptions were based on MMP-9 levels found in endotracheal aspirate of children with RSV-induced respiratory failure.<sup><xref rid="zoi200164r13" ref-type="bibr">13</xref></sup></p>
              </sec>
              <sec id="H2-8-ZOI200164">
                <title>Statistical Analysis</title>
                <p>Means, standard deviations, medians, quartiles, and ranges (minimum, maximum) were used to describe continuous variables, and counts and percentages were used for categorical variables. To compare baseline characteristics among the treatment groups, we used the Kruskal-Wallis test for age, height, and weight due to evidence of nonnormality of the distribution of the values. We used either χ<sup>2</sup> or Fisher exact test for categorical variables depending on expected cell counts.</p>
                <p>We analyzed inflammatory markers by first performing log<sub>10</sub> transformation to address the skewedness of the distribution and extreme outliers. We then calculated the difference at each point relative to baseline to obtain the change (ie, pretreatment and posttreatment) outcome and fitted a generalized linear mixed model with random intercepts and assumed unequal variances across treatment groups with change from baseline as the outcome. The Bonferroni approach was used to adjust for multiple testing (with a 2-tailed <italic>P</italic>  &lt;  .002 as the threshold for statistical significance) and simultaneous confidence intervals (99.8% confidence level).</p>
                <p>For clinical outcomes (measured in number of days), we used a generalized linear model assuming a negative binomial distribution using log link function to address possible overdispersion due to some extreme observations. For this set of analyses, a 2-tailed <italic>P</italic> &lt; .05 was set as the level of significance, with 95% CIs. All analyses were done using SAS version 9.4 (SAS Institute).</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI200164">
              <title>Results</title>
              <sec id="H2-9-ZOI200164">
                <title>Enrollment and Baseline Characteristics</title>
                <p>A total of 147 patients were screened, and 48 patients (32.7%) were randomized (<xref ref-type="fig" rid="zoi200164f1">Figure 1</xref>). All enrolled patients completed the study. The median (range) age of patients at randomization was 12 (1-125) months, with 36 (75.0%) younger than 2 years. Overall, 26 participants (54.2%) were boys, and 29 (60.4%) had a comorbidity. Baseline demographic characteristics were comparable among the 3 groups (eTable in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 2</xref>). At the time of randomization, 34 patients (70.8%) required mechanical ventilation, 2 (4.2%) received BiPAP support, and the remaining 12 patients (25.0%) received HFNC. Once extubated, 4 (11.8%) received BiPAP, and 22 (64.8%) were transitioned to HFNC. A total of 5 of 34 patients (14.7%) were extubated before day 3. No patients who initially received BiPAP or HFNC at randomization required intubation.</p>
                <fig id="zoi200164f1" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Flow Diagram of Trial</title>
                    <p>AZM indicates azithromycin.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-3-e203482-g001"/>
                </fig>
              </sec>
              <sec id="H2-10-ZOI200164">
                <title>Pharmacokinetics of AZM</title>
                <p>The pharmacokinetic parameters for AZM are listed in <xref rid="zoi200164t1" ref-type="table">Table 1</xref>. A linear dose-dependent response was observed for the mean (SD) AUC values of AZM in plasma between the standard-dose and high-dose groups (14.8 [5.5] μg x h/mL vs 25.3 [13.2] μg x h/mL), while a nonlinear dose response was noted for the endotracheal samples between AZM groups (892.4 [383.7] μg x h/mL vs 807.3 [331.0] μg x h/mL). We observed that mean (SD) C<sub>max</sub> values were higher in the high-dose group for plasma than in the standard-dose group (0.34 [0.06] μg/mL vs 0.22 [0.09] μg/mL; <italic>P</italic> &lt; .001) and comparable for corresponding endotracheal samples (8.7 [1.1] μg/mL vs 11.0 [1.5] μg/mL; <italic>P</italic> = .008). The times to C<sub>max</sub> were the same between dose groups for plasma and for endotracheal samples in the standard-dose group, but it was prolonged for the endotracheal samples in the high-dose group. An inverse dose-dependent penetration ratio (2:1) was observed in the endotracheal samples between the standard-dose and high-dose groups, respectively (48 h for the standard-dose group; 96 h for the high-dose group). This observation was due to comparable endotracheal AUC values between dose groups, while the plasma AUC values exhibited a linear dose dependent relationship. The comparable endotracheal AUC values were likely due to extensive distribution of AZM in the respiratory tract, resulting in drug saturation.</p>
                <table-wrap id="zoi200164t1" orientation="portrait" position="float">
                  <label>Table 1. </label>
                  <caption>
                    <title>Pharmacokinetic Parameters for Standard- and High-Dose AZM Using Urea-Corrected Data</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="31.34%" span="1"/>
                    <col width="15.23%" span="1"/>
                    <col width="19.09%" span="1"/>
                    <col width="15.23%" span="1"/>
                    <col width="19.11%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="3" valign="top" align="left" scope="col" colspan="1">Parameter</th>
                        <th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SD)</th>
                      </tr>
                      <tr>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Receiving 10 mg/kg AZM</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Receiving 20 mg/kg AZM</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Plasma</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Endotracheal</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Plasma</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Endotracheal</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">C<sub>max</sub>, μg/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.22 (0.09)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (1.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.34 (0.06)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.7 (1.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">T<sub>max</sub>, h</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">48</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">96</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">AUC, 0-144 h, μg × h/mL</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14.8 (5.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">892.4 (383.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">25.3 (13.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">807.3 (331)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">AUC<sub>endotracheal</sub> / AUC<sub>plasma</sub></td>
                        <td colspan="2" valign="top" align="left" rowspan="1">60.3</td>
                        <td colspan="2" valign="top" align="left" rowspan="1">31.9</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Half-life, h</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">76 (17)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">78 (31)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">102 (33)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">385 (63)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: AUC, area under the curve; AZM, azithromycin; C<sub>max</sub>, peak plasma levels; T<sub>max</sub>, time to peak plasma levels.</p>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
              <sec id="H2-11-ZOI200164">
                <title>Safety Profile and Adverse Events</title>
                <p>All participants were monitored daily for adverse events using National Institutes of Health event recording<sup><xref rid="zoi200164r21" ref-type="bibr">21</xref></sup> from the time of study enrollment until discharge from the PICU. No gastrointestinal adverse events (ie, diarrhea, vomiting, or abdominal distention), feeding intolerance, thrush, intravenous site reactions, or rash were documented in any of the study participants. We measured QT interval corrected for heart rate daily during the treatment phase, and all were within normal range. There were no abnormal vital signs or arrhythmias noted during or within 4 hours of drug administration. Finally, no abnormal laboratory values attributable to the study drug were documented.</p>
              </sec>
              <sec id="H2-12-ZOI200164">
                <title>Profiles of MMP-9 and Cytokine Levels at Baseline and After Treatment</title>
                <p>In nasal secretions, compared with baseline values, no difference was noted in active and total MMP-9 levels or the level of its natural inhibitor, TIMP-1, at hour 48 or hour 72 after treatment started in all 3 groups (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>A, <xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>B, and <xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>C). At 48 hours after treatment began, the endotracheal aspirates showed that active MMP-9 was 0.4 log lower (99.8% CI, −1.07 to 0.28; <italic>P</italic> = .051) in the placebo group, 0.3 log lower (99.8% CI, −1.42 to 0.85; <italic>P</italic> = .39) in the standard-dose AZM group, and 0.5 log lower (99.8% CI, −1.04 to 0.14; <italic>P</italic> = .01) in the high-dose AZM group compared with baseline values (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>D). At 72 hours after treatment began, active MMP-9 levels in endotracheal aspirates were 0.4 log lower (99.8% CI, −1.45 to 0.70; <italic>P</italic> = .23) in the placebo group, 0.4 log lower (99.8% CI, −1.86 to 1.05; <italic>P</italic> = .34) in the standard-dose AZM group, and 1.0 log lower (99.8% CI, −1.28 to −0.64; <italic>P</italic> &lt; .001) in the high-dose AZM group compared with baseline values (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>D).</p>
                <fig id="zoi200164f2" fig-type="figure" orientation="portrait" position="float">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Change in MMP-9 and TIMP-1 Levels</title>
                    <p>Each panel shows the estimate of means with 99.8% CIs, whereby treatment effect is defined as the change (ie, posttreatment minus pretreatment) at each day for a given treatment. Therefore, a nonzero mean difference indicates a treatment effect for the given day and treatment (placebo vs standard-dose azithromycin [AZM] vs high-dose AZM) for the cytokines measured in the nasal and endotracheal secretions. MMP-9 indicates matrix metalloproteinase–9; and TIMP-1, tissue inhibitor of metalloproteinase–1.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-3-e203482-g002"/>
                </fig>
                <p>At 48 hours after treatment began, total MMP-9 levels in endotracheal aspirates were 0.4 log lower (99.8% CI, −1.01 to 0.29; <italic>P</italic> = .06) in the placebo group, 0.5 log lower (99.8% CI, −1.98 to 0.89; <italic>P</italic> = .20) in the standard-dose AZM group, and 0.5 log lower (99.8% CI, −0.92 to 0.02; <italic>P</italic> = .003) in the high-dose AZM group compared with baseline values (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>E). At 72 hours after treatment began, total MMP-9 in endotracheal aspirates was 0.4 log lower (99.8% CI, −1.26 to 0.52; <italic>P</italic> = .16) in the placebo group, 0.5 log lower (99.8% CI, −1.80 to 0.86; <italic>P</italic> = .23) in the standard-dose AZM group, and nearly 0.97 log lower (99.8% CI, −1.37 to −0.57; <italic>P</italic> &lt; .001) in the high-dose AZM group compared with baseline values (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>E). No significant difference was observed in endotracheal TIMP-1 values before and after treatment among the placebo and AZM groups (<xref ref-type="fig" rid="zoi200164f2">Figure 2</xref>F). Endotracheal TNF-α was 1.2 log lower (TNF-α: 99.8% CI, −1.92 to −0.47; <italic>P</italic> &lt; .001) and IL-1 was 1.1 log lower (99.8% CI, −1.77 to −0.35; <italic>P</italic> &lt; .001) in the high-dose AZM group 48 hours after treatment began compared with baseline (eFigures 1A and 1B in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 2</xref>). Likewise, endotracheal IL-10 was 0.84 log lower (99.8% CI, −1.48 to −0.21; <italic>P</italic> &lt; .001) at hour 48 and 1.2 logs lower (99.8% CI, −1.74 to −0.58; <italic>P</italic> &lt; .001) 72 hours after treatment began compared with baseline in the high-dose AZM group (eFigure 1C in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 2</xref>). No significant differences were observed for nasal TNF-α, IL-1, and IL-10 or for nasal and endotracheal INF-γ, IL-2, IL-6, IL-8, IL-12, and IL-13 in the placebo and both AZM groups (data not shown). Absolute concentrations of nasal active MMP-9, total MMP-9, and TIMP-1 as well as endotracheal active MMP-9, total MMP-9, TIMP-1, TNF-α, IL-1, and IL-10 are shown for pretreatment, 48 hours after treatment began, and 72 hours after treatment began in eFigure 2 in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 2</xref>.</p>
              </sec>
              <sec id="H2-13-ZOI200164">
                <title>Viral Load</title>
                <p>At baseline, the mean (SD) RSV load measured in the endotracheal aspirate was no different among the 3 groups at 2.6 (1.0) log<sub>10</sub> plaque-forming unit (PFU)/mL in the placebo group, 2.5 (1.5) log<sub>10</sub> PFU/mL in the standard-dose AZM group, and 2.1 (0.8) log<sub>10</sub> PFU/mL in the high-dose AZM group. On day 2 of treatment, the mean (SD) RSV load decreased to 1.2 (0.5) log<sub>10</sub> PFU/mL in the placebo group, 1.2 (0.5) log<sub>10</sub> PFU/mL in the standard-dose AZM group, and 0.36 (0.2) log<sub>10</sub> PFU/mL in the high-dose AZM group. On day 3 of treatment, the mean (SD) RSV load was lowest in the high-dose AZM group, at 0.1 (0.1) log<sub>10</sub> PFU/mL compared with 1.1 (0.4) log10 PFU/mL in the standard-dose AZM group, and 0.4 (0.3) log<sub>10</sub> PFU/mL in the placebo group, but this did not reach statistical significance (<italic>P</italic> = .49) (eFigure 3A and 3B in <xref ref-type="supplementary-material" rid="note-ZOI200164-1-s">Supplement 2</xref>). Nasal RSV titer correlated positively with INF-γ on day 3 (<italic>R</italic><sup>2</sup> = 0.47; <italic>P</italic> = .002). For children who were intubated, endotracheal RSV titer positively correlated with INF-γ at randomization (<italic>R</italic><sup>2</sup> = 0.44; <italic>P</italic> = .01) and, for the treatment group, at 24 hours after treatment began (<italic>R</italic><sup>2</sup> = 0.64; <italic>P</italic> = .004) and 48 hours after treatment began (<italic>R</italic><sup>2</sup> = 0.52; <italic>P</italic> = .05). No correlation was seen between viral titer and all other measured cytokines in both the nasal and endotracheal aspirate (data not shown).</p>
              </sec>
              <sec id="H2-14-ZOI200164">
                <title>Clinical Outcomes</title>
                <p><xref rid="zoi200164t2" ref-type="table">Table 2</xref> summarizes the clinical outcome findings (ie, days of ventilator support, mechanical ventilation, BiPAP, HFNC, oxygenation, durations of PICU and hospital stay, and presence of multiorgan failure) for the entire study cohort as well as for the placebo and AZM treatment groups separately. <xref rid="zoi200164t3" ref-type="table">Table 3</xref> summarizes the overall treatment effect on clinical variables and by group comparisons. Median (interquartile range) length of hospital stay was lower in the high-dose group than the placebo group (8 [6-14] days vs 11 [8-20] days; mean ratio estimate, 0.57; 95 CI, 0.38-0.87; <italic>P</italic> = .01).</p>
                <table-wrap id="zoi200164t2" orientation="portrait" position="float">
                  <?xpp 2col?>
                  <label>Table 2. </label>
                  <caption>
                    <title>Clinical Outcome Measures</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="18.73%" span="1"/>
                    <col width="15.63%" span="1"/>
                    <col width="16.67%" span="1"/>
                    <col width="15.63%" span="1"/>
                    <col width="15.63%" span="1"/>
                    <col width="17.71%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">All (N = 48)</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Placebo (n = 16)</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">AZM</th>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value for treatment effect<xref ref-type="table-fn" rid="zoi200164t2n1"><sup>a</sup></xref></th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">10 mg/kg (n = 16)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">20 mg/kg (n = 16)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ventilator support, d<xref ref-type="table-fn" rid="zoi200164t2n2"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.3 (8.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11.6 (13.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.4 (6.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.9 (2.9)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.06</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (3-11) [1-56]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (4-14) [2-56]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (3-14) [1-20]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (3-7) [1-11]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Mechanical ventilation, d<xref ref-type="table-fn" rid="zoi200164t2n3"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.3 (4.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4.8 (3.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5.6 (5.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (2.8)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.54</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (0-7) [0-16]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (3-8) [0-11]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (0-10) [0-16]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0-5) [0-8]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">BiPAP, d<xref ref-type="table-fn" rid="zoi200164t2n4"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.4 (7.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.6 (13.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.4 (1.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.1 (0.3)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.02<xref ref-type="table-fn" rid="zoi200164t2n5"><sup>e</sup></xref></td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0) [0-53]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0) [0-53]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0) [0-6]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0 (0-0) [0-1]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">HFNC, d<xref ref-type="table-fn" rid="zoi200164t2n6"><sup>f</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.6 (3.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3.3 (4.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.4 (2.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2.3 (1.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.81</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1-3) [0-18]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (0-3) [0-18]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1-5) [0-6]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (1-3) [0-6]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Oxygen, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.1 (6.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11.0 (8.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.6 (5.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6.6 (4.0)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.10</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (4-13) [2-31]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (5-16) [2-31]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (5-16) [2-20]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-8) [2-15]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">PICU stay, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.1 (4.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7.7 (4.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8.1 (5.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5.4 (2.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.09</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (4-10) [2-19]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">7 (5-10) [2-19]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4-13) [2-19]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (4-7) [2-11]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Hospital stay, d</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">12.2 (9.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15.8 (13.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11.8 (6.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">9.1 (4.7)</td>
                        <td rowspan="2" valign="middle" align="left" colspan="1">.04</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Median (IQR) [range]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (6-16) [2-57]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (8-20) [3-57]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (7-17) [4-25]</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6-14) [2-16]</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Multiorgan failure</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Yes</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (6.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (12.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (6.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45 (93.7)</td>
                        <td valign="middle" align="left" rowspan="1" colspan="1">14 (87.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">15 (93.8)</td>
                        <td valign="middle" align="left" rowspan="1" colspan="1">16 (100)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: AZM, azithromycin; BiPAP, bilevel positive airway pressure; HFNC, high-flow nasal cannula; IQR, interquartile range; PICU, pediatric intensive care unit.</p>
                    <fn id="zoi200164t2n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p><italic>P</italic> value and estimates with 95% confidence intervals for ratio of means based on fitting a generalized linear model assuming negative binomial distribution.</p>
                    </fn>
                    <fn id="zoi200164t2n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Ventilator support days is the sum of mechanical ventilation, BiPAP, and HFNC days.</p>
                    </fn>
                    <fn id="zoi200164t2n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>At randomization, there were 34 intubated patients (70.8%); 13 (81.3%) in the placebo group, 11 (68.8%) in the group receiving AZM 10 mg/kg, and 10 (62.5%) in the group receiving AZM 20 mg/kg.</p>
                    </fn>
                    <fn id="zoi200164t2n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>At randomization, there were 2 patients (4.2%) receiving BiPAP; 1 (6.3%) in the placebo group and 1 (6.3%) in the group receiving AZM 20 mg/kg.</p>
                    </fn>
                    <fn id="zoi200164t2n5">
                      <label>
                        <sup>e</sup>
                      </label>
                      <p>There was an outlier in the placebo group who received BiPAP for 53 days. This patient had congenital myopathy and was unable to wean off BiPAP and received a tracheostomy before discharge home on positive pressure ventilation. When this outlier was removed, revised analyses changed BiPAP treatment effect (<italic>P</italic> = .13), with pairwise comparison <italic>P</italic> values of .05 (AZM 20 vs AZM 10), .61 (AZM 10 vs placebo) and .13 (AZM 20 vs placebo); and ventilation support treatment effect (<italic>P</italic>  = .03), with pairwise comparison <italic>P</italic> values of .02 (AZM 20 vs AZM 10), .93 (AZM 10 vs placebo), and .02 (AZM 20 vs placebo).</p>
                    </fn>
                    <fn id="zoi200164t2n6">
                      <label>
                        <sup>f</sup>
                      </label>
                      <p>At randomization, there were 12 patients (25.0%) receiving HFNC; 2 (12.5%) in the placebo group, 5 (31.3%) in the group receiving AZM 10 mg/kg, and 5 (31.3%) in the group receiving AZM 20 mg/kg.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <table-wrap id="zoi200164t3" orientation="portrait" position="float">
                  <label>Table 3. </label>
                  <caption>
                    <title>Mean Ratio Estimates for Clinical Outcomes</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="20.16%" span="1"/>
                    <col width="12.31%" span="1"/>
                    <col width="12.31%" span="1"/>
                    <col width="12.31%" span="1"/>
                    <col width="12.31%" span="1"/>
                    <col width="15.3%" span="1"/>
                    <col width="15.3%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">AZM 20 mg/kg vs AZM 10 mg/kg </th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">AZM 10 mg/kg vs Placebo</th>
                        <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">AZM 20 mg/kg vs Placebo</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">Mean ratio estimate (95% CI)<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mean ratio estimate (95% CI)<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Mean ratio estimate (95% CI)<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic>P</italic> value<xref ref-type="table-fn" rid="zoi200164t3n1"><sup>a</sup></xref></th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ventilator support</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.59 (0.15-2.35)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.44</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.17-3.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.43 (0.21-0.86)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Mechanical ventilation</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.47 (0.07-2.98)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.41</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.18 (0.20-7.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.85</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.55 (0.17-1.80)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.32</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BiPAP</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.14 (0.02-1.18)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.07</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.12 (0.00-4.49)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.25</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.02 (0.00-0.44)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.02</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">HFNC</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.95 (0.30-3.04)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.93</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.17-3.21)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.67</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.22-2.20)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.52</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Oxygen</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.69 (0.43-1.10)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.12</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.87 (0.55-1.37)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.54</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.60 (0.38-0.97)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.04</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">PICU stay</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.67 (0.45-1.02)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.06</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1.05 (0.69-1.60)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.82</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.71 (0.49-1.02)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.07</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hospital stay</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.77 (0.53-1.13)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.18</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.74 (0.49-1.14)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.17</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0.57 (0.38-0.87)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: AZM, azithromycin; BiPAP, bilevel positive airway pressure; HFNC, high-flow nasal cannula; PICU, pediatric intensive care unit.</p>
                    <fn id="zoi200164t3n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p><italic>P</italic> value and estimates with 95% confidence intervals for ratio of means based on fitting a generalized linear model assuming negative binomial distribution.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
              </sec>
            </sec>
            <sec id="H1-4-ZOI200164">
              <title>Discussion</title>
              <p>To the best of our knowledge, this is the first randomized placebo-controlled trial of AZM at multiple doses in children with severe RSV infection and lung disease who required PICU management and positive pressure ventilation. We demonstrated preliminary efficacy of AZM, specifically at a higher dose, in the reduction of biomarkers modulated by RSV infection and in reducing duration of hospitalization in a critically ill cohort of hospitalized children.</p>
              <p>Disease severity in RSV infection has been linked with excessive release of cytokines.<sup><xref rid="zoi200164r22" ref-type="bibr">22</xref>,<xref rid="zoi200164r23" ref-type="bibr">23</xref>,<xref rid="zoi200164r24" ref-type="bibr">24</xref>,<xref rid="zoi200164r25" ref-type="bibr">25</xref>,<xref rid="zoi200164r26" ref-type="bibr">26</xref>,<xref rid="zoi200164r27" ref-type="bibr">27</xref></sup> Previous studies have shown that AZM attenuates cytokine production, which may reduce the disease severity seen in respiratory viral infections.<sup><xref rid="zoi200164r28" ref-type="bibr">28</xref></sup> Furthermore, preclinical studies have shown the antiviral effects of AZM.<sup><xref rid="zoi200164r29" ref-type="bibr">29</xref>,<xref rid="zoi200164r30" ref-type="bibr">30</xref></sup> Given these properties, AZM has been studied for its potential use as targeted therapy for a wide spectrum of viral respiratory infections, including RSV. However, clinical trials of AZM and other macrolides in RSV infection have yielded conflicting results. In the first trial by Tahan et al,<sup><xref rid="zoi200164r31" ref-type="bibr">31</xref></sup> the investigators reported that treatment with clarithromycin reduced hospital length of stay and supplemental oxygen need compared with placebo. In contrast, subsequent trials using enteral AZM failed to demonstrate any clinical benefit.<sup><xref rid="zoi200164r32" ref-type="bibr">32</xref>,<xref rid="zoi200164r33" ref-type="bibr">33</xref>,<xref rid="zoi200164r34" ref-type="bibr">34</xref>,<xref rid="zoi200164r35" ref-type="bibr">35</xref></sup> In previously reported negative trials, the study design, including patient population (non-ICU patients), macrolide dosing (1-3 doses during 1-14 days), and route of AZM administration (enteral) likely contributed to the difference seen in the findings of this trial. In a 2015 trial,<sup><xref rid="zoi200164r15" ref-type="bibr">15</xref></sup> treatment of RSV bronchiolitis with AZM reduced overall respiratory morbidity and, in another,<sup><xref rid="zoi200164r36" ref-type="bibr">36</xref></sup> decreased the progression to severe lower respiratory tract infection in preschool children.</p>
              <p>Given the uncertainty regarding optimal dosing to achieve anti-inflammatory activity, we included a high-dose AZM group to maximize the likelihood of achieving adequate and sustained AZM levels. Others have suggested increased effectiveness of high-dose AZM in <italic>Ureaplasma urealyticum</italic> clearance in preterm infants.<sup><xref rid="zoi200164r37" ref-type="bibr">37</xref>,<xref rid="zoi200164r38" ref-type="bibr">38</xref>,<xref rid="zoi200164r39" ref-type="bibr">39</xref></sup> In this study, we demonstrated that high doses of AZM were safe. Although the nasal levels of MMP-9, TIMP-1, and the other RSV-related cytokines were similar among the placebo and AZM treatment groups, endotracheal active and total MMP-9, TNF-α, IL-1, and IL-10 were lower after treatment in the high-dose AZM group compared with baseline values. We also observed that RSV titer in the nasal and lung compartment decreased among all patients, and although those treated with high doses of AZM had the lowest viral burden at the end of the third dose, this finding was not significant. Although exploratory in nature, we also found that the median number of hospital days was approximately 3 days less in the high-dose group compared with the placebo group.</p>
              <sec id="H2-15-ZOI200164">
                <title>Limitations</title>
                <p>This study has limitations, including its small sample size. Although we observed decreased numbers of ventilator support and oxygen days as well as shorter duration of PICU stay in the high-dose AZM group, future studies will need to be powered to detect changes in these clinical outcome measures based on the findings of this trial. Also, it is possible that practice variation might have contributed to the clinical differences seen between the placebo vs treatment group. However, the masking of the study ensured no biases toward any particular group, and practice variation was also limited given that our unit in general follows the same respiratory weaning protocol. Furthermore, sensorineural hearing loss is a possible, although rare, adverse effect of AZM use and was not tested in our patients.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI200164">
              <title>Conclusions</title>
              <p>We found that both doses of AZM were safe. No difference was observed in nasal MMP-9 levels across all groups. Patients who received high-dose AZM had lower endotracheal MMP-9 levels and had fewer hospitalization days. This trial provides the necessary foundation to plan a larger, multicenter randomized clinical trial that will be critical in determining the clinical effectiveness of high-dose AZM among children with severe RSV lung disease.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI200164">
              <title>References</title>
              <ref id="zoi200164r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Nair</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Nokes</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Gessner</surname><given-names>BD</given-names></name>, <etal/></person-group><article-title>Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis</article-title>. <source>Lancet</source>. <year>2010</year>;<volume>375</volume>(<issue>9725</issue>):-. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(10)60206-1</pub-id><?supplied-pmid 20399493?><pub-id pub-id-type="pmid">20399493</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Shi</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Balsells</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wastnedge</surname><given-names>E</given-names></name>, <etal/></person-group><article-title>Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis</article-title>. <source>J Glob Health</source>. <year>2015</year>;<volume>5</volume>(<issue>2</issue>):<elocation-id>020416</elocation-id>. doi:<pub-id pub-id-type="doi">10.7189/jogh.05.020416</pub-id><?supplied-pmid 26682048?><pub-id pub-id-type="pmid">26682048</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Buckingham</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Quasney</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Bush</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>DeVincenzo</surname><given-names>JP</given-names></name></person-group><article-title>Respiratory syncytial virus infections in the pediatric intensive care unit: clinical characteristics and risk factors for adverse outcomes</article-title>. <source>Pediatr Crit Care Med</source>. <year>2001</year>;<volume>2</volume>(<issue>4</issue>):<fpage>318</fpage>-<lpage>323</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00130478-200110000-00006</pub-id><?supplied-pmid 12793934?><pub-id pub-id-type="pmid">12793934</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Franklin</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Fraser</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Schibler</surname><given-names>A</given-names></name></person-group><article-title>Respiratory support for infants with bronchiolitis, a narrative review of the literature</article-title>. <source>Paediatr Respir Rev</source>. <year>2019</year>;<volume>30</volume>:<fpage>16</fpage>-<lpage>24</lpage>.<?supplied-pmid 31076380?><pub-id pub-id-type="pmid">31076380</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kong</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Gaggar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Winkler</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Blalock</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Clancy</surname><given-names>JP</given-names></name></person-group><article-title>Matrix metalloproteinase activity in pediatric acute lung injury</article-title>. <source>Int J Med Sci</source>. <year>2009</year>;<volume>6</volume>(<issue>1</issue>):<fpage>9</fpage>-<lpage>17</lpage>. doi:<pub-id pub-id-type="doi">10.7150/ijms.6.9</pub-id><?supplied-pmid 19159011?><pub-id pub-id-type="pmid">19159011</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Zinter</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Delucchi</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Kong</surname><given-names>MY</given-names></name>, <etal/></person-group><article-title>Early plasma matrix metalloproteinase profiles: a novel pathway in pediatric acute respiratory distress syndrome</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2019</year>;<volume>199</volume>(<issue>2</issue>):<fpage>181</fpage>-<lpage>189</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201804-0678OC</pub-id><?supplied-pmid 30114376?><pub-id pub-id-type="pmid">30114376</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Devereux</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Steele</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Jagelman</surname><given-names>T</given-names></name>, <etal/></person-group><article-title>An observational study of matrix metalloproteinase (MMP)-9 in cystic fibrosis</article-title>. <source>J Cyst Fibros</source>. <year>2014</year>;<volume>13</volume>(<issue>5</issue>):<fpage>557</fpage>-<lpage>563</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcf.2014.01.010</pub-id><?supplied-pmid 24525080?><pub-id pub-id-type="pmid">24525080</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cederqvist</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Sorsa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Tervahartiala</surname><given-names>T</given-names></name>, <etal/></person-group><article-title>Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress</article-title>. <source>Pediatrics</source>. <year>2001</year>;<volume>108</volume>(<issue>3</issue>):<fpage>686</fpage>-<lpage>692</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.108.3.686</pub-id><?supplied-pmid 11533337?><pub-id pub-id-type="pmid">11533337</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Ma</surname><given-names>HP</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>XM</given-names></name></person-group><article-title>Matrix metalloproteinase 9 is involved in airway inflammation in cough variant asthma</article-title>. <source>Exp Ther Med</source>. <year>2014</year>;<volume>8</volume>(<issue>4</issue>):<fpage>1197</fpage>-<lpage>1200</lpage>. doi:<pub-id pub-id-type="doi">10.3892/etm.2014.1903</pub-id><?supplied-pmid 25187823?><pub-id pub-id-type="pmid">25187823</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Culpitt</surname><given-names>SV</given-names></name>, <name name-style="western"><surname>Rogers</surname><given-names>DF</given-names></name>, <name name-style="western"><surname>Traves</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Barnes</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Donnelly</surname><given-names>LE</given-names></name></person-group><article-title>Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma</article-title>. <source>Respir Med</source>. <year>2005</year>;<volume>99</volume>(<issue>6</issue>):<fpage>703</fpage>-<lpage>710</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.rmed.2004.10.022</pub-id><?supplied-pmid 15878486?><pub-id pub-id-type="pmid">15878486</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cataldo</surname><given-names>DD</given-names></name>, <name name-style="western"><surname>Bettiol</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Noël</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bartsch</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Foidart</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Louis</surname><given-names>R</given-names></name></person-group><article-title>Matrix metalloproteinase-9, but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum from allergic asthmatic patients after allergen challenge</article-title>. <source>Chest</source>. <year>2002</year>;<volume>122</volume>(<issue>5</issue>):<fpage>1553</fpage>-<lpage>1559</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.122.5.1553</pub-id><?supplied-pmid 12426252?><pub-id pub-id-type="pmid">12426252</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kong</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Whitley</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>N</given-names></name>, <etal/></person-group><article-title>Matrix metalloproteinase-9 mediates RSV infection in vitro and in vivo</article-title>. <source>Viruses</source>. <year>2015</year>;<volume>7</volume>(<issue>8</issue>):<fpage>4230</fpage>-<lpage>4253</lpage>. doi:<pub-id pub-id-type="doi">10.3390/v7082817</pub-id><?supplied-pmid 26264019?><pub-id pub-id-type="pmid">26264019</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r13">
                <label>13</label>
                <mixed-citation publication-type="book">Labro MT. <chapter-title>Intraphagocytic penetration of macrolides antibiotics</chapter-title> In: <person-group><name name-style="western"><surname>Bryskier</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Butzler</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Neu</surname><given-names>HC</given-names></name>, <name name-style="western"><surname>Tulkens</surname><given-names>PM</given-names></name></person-group>, eds. <source>Macrolides: Chemistry, Pharmacology, and Clinical Use</source>. <publisher-name>Arnette Blackwell</publisher-name>; <year>1993</year>:<fpage>379</fpage>-<lpage>388</lpage>.</mixed-citation>
              </ref>
              <ref id="zoi200164r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Cameron</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>McSharry</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Chaudhuri</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Farrow</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Thomson</surname><given-names>NC</given-names></name></person-group><article-title>Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments</article-title>. <source>Clin Exp Allergy</source>. <year>2012</year>;<volume>42</volume>(<issue>9</issue>):<fpage>1302</fpage>-<lpage>1312</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2222.2012.03979.x</pub-id><?supplied-pmid 22925316?><pub-id pub-id-type="pmid">22925316</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Beigelman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Isaacson-Schmid</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sajol</surname><given-names>G</given-names></name>, <etal/></person-group><article-title>Randomized trial to evaluate azithromycin’s effects on serum and upper airway IL-8 levels and recurrent wheezing in infants with respiratory syncytial virus bronchiolitis</article-title>. <source>J Allergy Clin Immunol</source>. <year>2015</year>;<volume>135</volume>(<issue>5</issue>):<fpage>1171</fpage>-<lpage>8.e1</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaci.2014.10.001</pub-id><?supplied-pmid 25458910?><pub-id pub-id-type="pmid">25458910</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><collab>American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis</collab></person-group><article-title>Diagnosis and management of bronchiolitis</article-title>. <source>Pediatrics</source>. <year>2006</year>;<volume>118</volume>(<issue>4</issue>):<fpage>1774</fpage>-<lpage>1793</lpage>. doi:<pub-id pub-id-type="doi">10.1542/peds.2006-2223</pub-id><?supplied-pmid 17015575?><pub-id pub-id-type="pmid">17015575</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Schulz</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name>, <name name-style="western"><surname>Moher</surname><given-names>D</given-names></name>; <collab>CONSORT Group</collab></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title>. <source>Ann Intern Med</source>. <year>2010</year>;<volume>152</volume>(<issue>11</issue>):<fpage>726</fpage>-<lpage>732</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-152-11-201006010-00232</pub-id><?supplied-pmid 20335313?><pub-id pub-id-type="pmid">20335313</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Rennard</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Basset</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Lecossier</surname><given-names>D</given-names></name>, <etal/></person-group><article-title>Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution</article-title>. <source>J Appl Physiol (1985)</source>. <year>1986</year>;<volume>60</volume>(<issue>2</issue>):<fpage>532</fpage>-<lpage>538</lpage>. doi:<pub-id pub-id-type="doi">10.1152/jappl.1986.60.2.532</pub-id><?supplied-pmid 3512509?><pub-id pub-id-type="pmid">3512509</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bouzas</surname><given-names>ML</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>JR</given-names></name>, <name name-style="western"><surname>Queiroz</surname><given-names>A</given-names></name>, <etal/>; <collab>Acute Respiratory Infection and Wheeze Study Group Phase I and II</collab></person-group><article-title>Diagnostic accuracy of digital RNA quantification versus real-time PCR for the detection of respiratory syncytial virus in nasopharyngeal aspirates from children with acute respiratory infection</article-title>. <source>J Clin Virol</source>. <year>2018</year>;<volume>106</volume>:<fpage>34</fpage>-<lpage>40</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jcv.2018.07.003</pub-id><?supplied-pmid 30031351?><pub-id pub-id-type="pmid">30031351</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Goldstein</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Giroir</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Randolph</surname><given-names>A</given-names></name>; <collab>International Consensus Conference on Pediatric Sepsis</collab></person-group><article-title>International Pediatric Sepsis Consensus Conference: definitions for sepsis and organ dysfunction in pediatrics</article-title>. <source>Pediatr Crit Care Med</source>. <year>2005</year>;<volume>6</volume>(<issue>1</issue>):<fpage>2</fpage>-<lpage>8</lpage>. doi:<pub-id pub-id-type="doi">10.1097/01.PCC.0000149131.72248.E6</pub-id><?supplied-pmid 15636651?><pub-id pub-id-type="pmid">15636651</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r21">
                <label>21</label>
                <mixed-citation publication-type="web"><person-group><collab>National Heart, Lung, and Blood Institute</collab></person-group> NHLBI adverse event and unanticipated problem reporting policy. Accessed March 17, 2020. <ext-link ext-link-type="uri" xlink:href="https://www.nhlbi.nih.gov/grants-and-training/policies-and-guidelines/nhlbi-adverse-event-and-unanticipated-problem-reporting-policy">https://www.nhlbi.nih.gov/grants-and-training/policies-and-guidelines/nhlbi-adverse-event-and-unanticipated-problem-reporting-policy</ext-link></mixed-citation>
              </ref>
              <ref id="zoi200164r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kong</surname><given-names>MY</given-names></name>, <name name-style="western"><surname>Clancy</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Peng</surname><given-names>N</given-names></name>, <etal/></person-group><article-title>Pulmonary matrix metalloproteinase-9 activity in mechanically ventilated children with respiratory syncytial virus</article-title>. <source>Eur Respir J</source>. <year>2014</year>;<volume>43</volume>(<issue>4</issue>):<fpage>1086</fpage>-<lpage>1096</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00105613</pub-id><?supplied-pmid 24311764?><pub-id pub-id-type="pmid">24311764</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Gern</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Anklam</surname><given-names>KA</given-names></name>, <etal/></person-group><article-title>Relationships among specific viral pathogens, virus-induced interleukin-8, and respiratory symptoms in infancy</article-title>. <source>Pediatr Allergy Immunol</source>. <year>2002</year>;<volume>13</volume>(<issue>6</issue>):<fpage>386</fpage>-<lpage>393</lpage>. doi:<pub-id pub-id-type="doi">10.1034/j.1399-3038.2002.01093.x</pub-id><?supplied-pmid 12485313?><pub-id pub-id-type="pmid">12485313</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Lee</surname><given-names>IT</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>CM</given-names></name></person-group><article-title>TNF-alpha induces matrix metalloproteinase-9 expression in A549 cells: role of TNFR1/TRAF2/PKCalpha-dependent signaling pathways</article-title>. <source>J Cell Physiol</source>. <year>2010</year>;<volume>224</volume>(<issue>2</issue>):<fpage>454</fpage>-<lpage>464</lpage>. doi:<pub-id pub-id-type="doi">10.1002/jcp.22142</pub-id><?supplied-pmid 20333651?><pub-id pub-id-type="pmid">20333651</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Rutigliano</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>BS</given-names></name></person-group><article-title>Prolonged production of TNF-α exacerbates illness during respiratory syncytial virus infection</article-title>. <source>J Immunol</source>. <year>2004</year>;<volume>173</volume>(<issue>5</issue>):<fpage>3408</fpage>-<lpage>3417</lpage>. doi:<pub-id pub-id-type="doi">10.4049/jimmunol.173.5.3408</pub-id><?supplied-pmid 15322205?><pub-id pub-id-type="pmid">15322205</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Murai</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Terada</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mizuno</surname><given-names>M</given-names></name>, <etal/></person-group><article-title>IL-10 and RANTES are elevated in nasopharyngeal secretions of children with respiratory syncytial virus infection</article-title>. <source>Allergol Int</source>. <year>2007</year>;<volume>56</volume>(<issue>2</issue>):<fpage>157</fpage>-<lpage>163</lpage>. doi:<pub-id pub-id-type="doi">10.2332/allergolint.O-06-454</pub-id><?supplied-pmid 17460443?><pub-id pub-id-type="pmid">17460443</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Tripp</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Oshansky</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Alvarez</surname><given-names>R</given-names></name></person-group><article-title>Cytokines and respiratory syncytial virus infection</article-title>. <source>Proc Am Thorac Soc</source>. <year>2005</year>;<volume>2</volume>(<issue>2</issue>):<fpage>147</fpage>-<lpage>149</lpage>. doi:<pub-id pub-id-type="doi">10.1513/pats.200502-014AW</pub-id><?supplied-pmid 16113483?><pub-id pub-id-type="pmid">16113483</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Mosquera</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>De Jesus-Rojas</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Stark</surname><given-names>JM</given-names></name>, <etal/></person-group><article-title>Role of prophylactic azithromycin to reduce airway inflammation and mortality in a RSV mouse infection model</article-title>. <source>Pediatr Pulmonol</source>. <year>2018</year>;<volume>53</volume>(<issue>5</issue>):<fpage>567</fpage>-<lpage>574</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.23956</pub-id><?supplied-pmid 29405608?><pub-id pub-id-type="pmid">29405608</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Gielen</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>MR</given-names></name></person-group><article-title>Azithromycin induces anti-viral responses in bronchial epithelial cells</article-title>. <source>Eur Respir J</source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>646</fpage>-<lpage>654</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00095809</pub-id><?supplied-pmid 20150207?><pub-id pub-id-type="pmid">20150207</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Schögler</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kopf</surname><given-names>BS</given-names></name>, <name name-style="western"><surname>Edwards</surname><given-names>MR</given-names></name>, <etal/></person-group><article-title>Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells</article-title>. <source>Eur Respir J</source>. <year>2015</year>;<volume>45</volume>(<issue>2</issue>):<fpage>428</fpage>-<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00102014</pub-id><?supplied-pmid 25359346?><pub-id pub-id-type="pmid">25359346</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Tahan</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ozcan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Koc</surname><given-names>N</given-names></name></person-group><article-title>Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial</article-title>. <source>Eur Respir J</source>. <year>2007</year>;<volume>29</volume>(<issue>1</issue>):<fpage>91</fpage>-<lpage>97</lpage>. doi:<pub-id pub-id-type="doi">10.1183/09031936.00029206</pub-id><?supplied-pmid 17050564?><pub-id pub-id-type="pmid">17050564</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Kneyber</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>van Woensel</surname><given-names>JB</given-names></name>, <name name-style="western"><surname>Uijtendaal</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Uiterwaal</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Kimpen</surname><given-names>JL</given-names></name>; <collab>Dutch Antibiotics in RSV Trial (DART) Research Group</collab></person-group><article-title>Azithromycin does not improve disease course in hospitalized infants with respiratory syncytial virus (RSV) lower respiratory tract disease: a randomized equivalence trial</article-title>. <source>Pediatr Pulmonol</source>. <year>2008</year>;<volume>43</volume>(<issue>2</issue>):<fpage>142</fpage>-<lpage>149</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ppul.20748</pub-id><?supplied-pmid 18085694?><pub-id pub-id-type="pmid">18085694</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Pinto</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Pitrez</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Luisi</surname><given-names>F</given-names></name>, <etal/></person-group><article-title>Azithromycin therapy in hospitalized infants with acute bronchiolitis is not associated with better clinical outcomes: a randomized, double-blinded, and placebo-controlled clinical trial</article-title>. <source>J Pediatr</source>. <year>2012</year>;<volume>161</volume>(<issue>6</issue>):<fpage>1104</fpage>-<lpage>1108</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jpeds.2012.05.053</pub-id><?supplied-pmid 22748516?><pub-id pub-id-type="pmid">22748516</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>McCallum</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Chatfield</surname><given-names>MD</given-names></name>, <etal/></person-group><article-title>A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial</article-title>. <source>PLoS One</source>. <year>2013</year>;<volume>8</volume>(<issue>9</issue>):<elocation-id>e74316</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0074316</pub-id><?supplied-pmid 24086334?><pub-id pub-id-type="pmid">24086334</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>McCallum</surname><given-names>GB</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Grimwood</surname><given-names>K</given-names></name>, <etal/></person-group><article-title>Three-weekly doses of azithromycin for indigenous infants hospitalized with bronchiolitis: a multicentre, randomized, placebo-controlled trial</article-title>. <source>Front Pediatr</source>. <year>2015</year>;<volume>3</volume>:<fpage>32</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fped.2015.00032</pub-id><?supplied-pmid 25954737?><pub-id pub-id-type="pmid">25954737</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Bacharier</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Guilbert</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Mauger</surname><given-names>DT</given-names></name>, <etal/></person-group><article-title>Early administration of azithromycin and prevention of severe lower respiratory tract illnesses in preschool children with a history of such illnesses: a randomized clinical trial</article-title>. <source>JAMA</source>. <year>2015</year>;<volume>314</volume>(<issue>19</issue>):<fpage>2034</fpage>-<lpage>2044</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2015.13896</pub-id><?supplied-pmid 26575060?><pub-id pub-id-type="pmid">26575060</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Hassan</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Othman</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Eddington</surname><given-names>ND</given-names></name>, <etal/></person-group><article-title>Pharmacokinetics, safety, and biologic effects of azithromycin in extremely preterm infants at risk for ureaplasma colonization and bronchopulmonary dysplasia</article-title>. <source>J Clin Pharmacol</source>. <year>2011</year>;<volume>51</volume>(<issue>9</issue>):<fpage>1264</fpage>-<lpage>1275</lpage>. doi:<pub-id pub-id-type="doi">10.1177/0091270010382021</pub-id><?supplied-pmid 21098694?><pub-id pub-id-type="pmid">21098694</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Viscardi</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Othman</surname><given-names>AA</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>HE</given-names></name>, <etal/></person-group><article-title>Azithromycin to prevent bronchopulmonary dysplasia in ureaplasma-infected preterm infants: pharmacokinetics, safety, microbial response, and clinical outcomes with a 20-milligram-per-kilogram single intravenous dose</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2013</year>;<volume>57</volume>(<issue>5</issue>):<fpage>2127</fpage>-<lpage>2133</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.02183-12</pub-id><?supplied-pmid 23439637?><pub-id pub-id-type="pmid">23439637</pub-id></mixed-citation>
              </ref>
              <ref id="zoi200164r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><name name-style="western"><surname>Merchan</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Hassan</surname><given-names>HE</given-names></name>, <name name-style="western"><surname>Terrin</surname><given-names>ML</given-names></name>, <etal/></person-group><article-title>Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for <italic>Ureaplasma</italic> respiratory colonization</article-title>. <source>Antimicrob Agents Chemother</source>. <year>2015</year>;<volume>59</volume>(<issue>1</issue>):<fpage>570</fpage>-<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1128/AAC.03951-14</pub-id><?supplied-pmid 25385115?><pub-id pub-id-type="pmid">25385115</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI200164-1">
              <supplementary-material content-type="local-data" id="note-ZOI200164-1-s">
                <label>Supplement 1.</label>
                <caption>
                  <p>
                    <bold>Trial Procotol</bold>
                  </p>
                </caption>
                <media xlink:href="jamanetwopen-3-e203482-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eFigure 1.</bold> Endotracheal TNF-α, IL-1 and IL-10 Levels in the High-Dose Azithromycin Group After Treatment</p>
                  <p><bold>eFigure 2.</bold> Cytokine Levels Measured in the Nasal and Endotracheal Compartment Among All Groups at Baseline (Day 1), Day 2, and Day 3</p>
                  <p><bold>eFigure 3.</bold> RSV Titer Measured Over Time for Patients in All 3 Groups</p>
                  <p><bold>eTable. </bold>Demographic and Clinical Characteristics at Baseline</p>
                </caption>
                <media xlink:href="jamanetwopen-3-e203482-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
                    <bold>Data Sharing Statement</bold>
                  </p>
                </caption>
                <media xlink:href="jamanetwopen-3-e203482-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
